排序方式: 共有62条查询结果,搜索用时 31 毫秒
21.
Survivors of standard risk acute lymphoblastic leukemia do not have increased risk for overweight and obesity compared to non‐cancer peers: A report from the Children's Oncology Group 下载免费PDF全文
22.
23.
24.
25.
Alicia I. Arbaje MD MPH Devan L. Kansagara MD MCR FACP Amanda H. Salanitro MD MS MSPH Honora L. Englander MD Sunil Kripalani MD MSc Stephen F. Jencks MD MPH Lee A. Lindquist MD MBA 《Journal of general internal medicine》2014,29(6):932-939
With its focus on holistic approaches to patient care, caregiver support, and delivery system redesign, geriatrics has advanced our understanding of optimal care during transitions. This article provides a framework for incorporating geriatrics principles into care transition activities by discussing the following elements: (1) identifying factors that make transitions more complex, (2) engaging care “receivers” and tailoring home care to meet patient needs, (3) building “recovery plans” into transitional care, (4) predicting and avoiding preventable readmissions, and (5) adopting a palliative approach, when appropriate, that optimizes patient and family goals of care. The article concludes with a discussion of practical aspects of designing, implementing, and evaluating care transitions programs for those with complex care needs, as well as implications for public policy. 相似文献
26.
Boaz Tadmor MD LTC John McManus MD MCR Kristi L. Koenig MD 《Academic emergency medicine》2006,13(11):1130-1134
In a disaster or mass casualty incident, health care resources may be exceeded and systems may be challenged by unusual requirements. These resources may include pharmaceuticals, supplies, and equipment as well as certain types of academic and administrative expertise. New agencies and decision makers may need to work together in an unfamiliar environment. Furthermore, large numbers of casualties needing treatment, newer therapies required to care for these casualties, and increased workforce and space available for these casualties all contribute to what is often referred to as "surge." Surge capacity in emergency care can be described in technical, scientific terms that are measured by numbers and benchmarks (e.g., beds, patients, and medications) or can take on a more conceptual and abstract form (e.g., decisions, authority, and responsibility). The former may be referred to as the "science" of surge, whereas the latter, an equal if not more important component of surge systems that is more conceptual and abstract, can be considered the "art" of surge. The experiences from Israel and the U.S. military may serve to educate colleagues who may be required to respond or react to an event that taxes the current health care system. This report presents concrete examples of surge capacity strategies used by both Israel and the U.S. military and provides solutions that may be applied to other health care systems when faced with similar situations. 相似文献
27.
Laparoscopic ischemic conditioning of the stomach increases neovascularization of the gastric conduit in patients undergoing esophagectomy for cancer 下载免费PDF全文
28.
Improvements in hospice utilization among patients with advanced‐stage lung cancer in an integrated health care system 下载免费PDF全文
29.
Developing drugs for treatment of atopic dermatitis in children (≥3 months to <18 years of age): Draft guidance for industry 下载免费PDF全文
Elaine C. Siegfried MD Jennifer C. Jaworski MS Lawrence F. Eichenfield MD Amy Paller MD MS Adelaide A. Hebert MD Eric L. Simpson MD MCR Emily Altman MD Charles Arena MD Andrew Blauvelt MD MBA Julie Block BA Mark Boguniewicz MD Suephy Chen MD MS Kelly Cordoro MD Diane Hanna DNP Kimberly Horii MD Thomas Hultsch MD PhD James Lee MD PhD Donald Y. Leung MD PhD Peter Lio MD Joshua Milner MD Theodore Omachi MD Christine Schneider PhD LSC Lynda Schneider MD Robert Sidbury MD MPH Timothy Smith MPP Jeffrey Sugarman MD PhD Sharif Taha PhD Susan Tofte RN MS FNP‐C Megha Tollefson MD Wynnis L. Tom MD Dennis P. West PhD FCCP CIP Lucinda Whitney DNP APRN PMHNP‐BC Lee Zane MD MAS 《Pediatric dermatology》2018,35(3):303-322
Atopic dermatitis is the most common chronic skin disease, and it primarily affects children. Although atopic dermatitis (AD) has the highest effect on burden of skin disease, no high‐level studies have defined optimal therapy for severe disease. Corticosteroids have been used to treat AD since the 1950s and remain the only systemic medication with Food and Drug Administration approval for this indication in children, despite published guidelines of care that recommend against this option. Several clinical trials with level 1 evidence have supported the use of topical treatments for mild to moderate atopic dermatitis in adults and children, but these trials have had little consistency in protocol design. Consensus recommendations will help standardize clinical development and trial design for children. The Food and Drug Administration issues guidance documents for industry as a source for “the Agency's current thinking on a particular subject.” Although they are nonbinding, industry considers these documents to be the standard for clinical development and trial design. Our consensus group is the first to specifically address clinical trial design in this population. We developed a draft guidance document for industry, Developing Drugs for Treatment of Atopic Dermatitis in Children (≥3 months to <18 years of age). This draft guidance has been submitted to the Food and Drug Administration based on a provision in the Federal Register (Good Guidance Practices). 相似文献